Videos

AR Inhibitor Selection in Nonmetastatic Castration-Resistant Prostate Cancer

Matthew Krebs, MB, PhD spoke about the reasoning for the phase 1 PALOMA trial in patients with solid tumors who received a subcutaneous formulation of amivantamab.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Patient Scenario 1: nmCRPC Identification and Work-up

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Stéphane Champiat, MD, PhD, Reviews Results With IL-2/IL15 Superagonist SOT101 From AURELIO-03 Trial

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

Stéphane Champiat, MD, PhD

Discontinuing IO/IO Therapy in Intermediate-Risk Renal Cell Carcinoma

Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

RRMM: Ixazomib Plus Pomalidomide and Dexamethasone

Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.

Paul G. Richardson, MD;Cristina Gasparetto, MD

Patient Profile 2: Intermediate-Risk RCC Treated With Ipilimumab + Nivolumab

Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

Importance of MRD in Treating Patients With Multiple Myeloma

Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.

Paul G. Richardson, MD;Cristina Gasparetto, MD

Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL

Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.

$Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL$

Frederick Locke, MD

Evolving Treatment Landscape in Metastatic Prostate Cancer

Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.

Bobby Liaw, MD

Recent Updates in Prostate Cancer Care

A prostate cancer expert discusses promising and emerging treatments for prostate cancer.

Atish Choudhury, MD, PhD

Frontline Treatment Options for RAI-refractory DTC

Dr Choudhury shares recent updates from 2021 meetings including ASCO GU, AUA, and ESMO.

$Frontline Treatment Options for RAI-refractory DTC$

Lori Wirth, MD

Impact of GVHD on Leukemic Relapse and Patient Outcomes

Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

April 7th 2022

Hannah Choe, MD, guides the panel in a conversation on the protective effects of acute and chronic GVHD including the potential impact on leukemic relapse.

Defining Acute and Chronic GVHD: Signs and Symptoms

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

April 7th 2022

A panel of key opinion leaders in stem cell transplant and cellular immunotherapy reviews the hallmark signs and symptoms of acute GVHD.

Peter Humphrey, MD, PhD, Talks Multidisciplinary Aspects of Oncology Research

Peter Humphrey MD, PhD

April 7th 2022

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.

Anjali Hari, MD, Highlights the Rationale for Assessing HIPEC in Frail and Non-Frail Ovarian Cancer

Anjali Hari, MD

ADT Therapy in Prostate Cancer: Agonists vs Antagonists

Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Overview on Androgen Deprivation Therapy in Prostate Cancer

Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Ursula A. Matulonis, MD, Highlights the Potential of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.

Ursula A. Matulonis, MD

Ira Winer, MD, PhD, Reviews Results of the ARTISTRY-1 Trial in Ovarian Cancer

In a discussion with CancerNetwork®, Ursula A. Matulonis, MD, describes the potential of mirvetuximab soravtansine (IMGN853) as a treatment for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

Ira Winer, MD, PhD, FACOG

April 5th 2022

Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.

Anjali Hari, MD, Speaks to Survival/Safety Outcomes With HIPEC in Frail and Non-Frail Ovarian Cancer

Anjali Hari, MD

April 5th 2022

Anjali Hari, MD, discusses survival and safety outcomes with hyperthermic intraperitoneal chemotherapy in frail and non-frail patients with ovarian cancer.

First-Line Treatment Options for Transplant-Ineligible NDMM: Focus on MAIA Trial

Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD;Rafael Fonseca, MD

Treatment Duration and Response to Induction Therapy in Transplant-Eligible NDMM

A review of the available first-line treatment options for transplant-ineligible multiple myeloma, as well as the design and findings of the MAIA study.

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

Choosing a Combination Treatment for Advanced Renal Cell Carcinoma

Experts explain how to determine treatment duration and a successful response to induction therapy for transplant-eligible multiple myeloma.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma

A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

Trends in Prostate Cancer Care

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

Bobby Liaw, MD;Atish Choudhury, MD, PhD

Patient-Healthcare Provider Communication Regarding Challenges

Prostate cancer experts share exciting changes to the prostate cancer treatment landscape and how we are now better equipped to take care of patients with prostate cancer.

Bobby Liaw, MD

Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC

A prostate cancer expert reemphasizes importance of open communication between patients and healthcare providers.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD